BD Launches Family of Syringes Which Addresses Environmental Impact and Meets a Variety of Clinical Needs

Actualizado 15/08/2011 11:00:46 CET


- BD Emerald Saf-T Syringe is designed to address the needs of
healthcare workers who require protection from needlestick injuries.
- BD Emerald PRO is designed to address the needs of the
developing world. The infection control issue at the forefront of
healthcare delivery in these regions is preventing reuse of injection
devices and the potential spread of pathogens from patient to patient.
- All syringes in the BD Emerald Syringe product family are
designed to reduce medical waste effects in communities everywhere.

The BD Emerald Syringe product line builds upon BD's sustainability commitment, which has been recognized for achievements in environmental stewardship. In Newsweek's 2010 "Green Rankings" of the 500 largest U.S. corporations, BD ranked second in the Healthcare sector and 24th overall. As part of its commitment to sustainability, BD's worldwide headquarters and three of BD's U.S. manufacturing sites are offsetting 100 percent of their electricity use with renewable energy through green power purchases and renewable energy credits. To learn more about environmental stewardship at BD, visit http://www.bd.com/sustainability.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.

[TAB]

Contact:

Alyssa Zeff

Public Relations

+1-201-847-4358

alyssa_zeff@bd.com

[FTAB]

CONTACT: .


Contact:
Alyssa Zeff
Public Relations
+1-201-847-4358
alyssa_zeff@bd.com

CONTACT: .

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación